Symbols / VRTX Stock $448.29 +3.01% Vertex Pharmaceuticals Incorporated

Healthcare • Biotechnology • United States • NMS
VRTX (Stock) Chart
O: — H: — L: — C: — V: —
SMA 20: — SMA 50: — SMA 200: —
Stock Fundamentals
Scroll to Statements
Index EQUITY
Sector Healthcare
Industry Biotechnology
CEO Dr. Reshma Kewalramani FASN, M.D.
Exch · Country NMS · United States
Market Cap 113.78B
Enterprise Value 108.52B
Income 4.34B
Sales 12.22B
FCF (ttm) 2.78B
Book/sh 76.18
Cash/sh 28.55
Employees 6,400
Insider 10d —
IPO Jul 24, 1991
Div forward ($/yr)
Div TTM ($/yr)
Dividend Yield
Ex-Div Date
5Y Avg Yield
Yield vs 5Y Avg
Payout 0.00%
P/E 26.59
Forward P/E 20.77
PEG 1.62
P/S 9.31
P/B 5.88
P/C —
EV/EBITDA 21.79
EV/Sales 8.88
Quick Ratio 2.38
Current Ratio 3.02
Debt/Eq 10.26
LT Debt/Eq —
EPS (ttm) 16.86
EPS next Y 21.59
EPS Growth 61.40%
Revenue Growth 7.80%
EPS Gr Q/Q 59.60%
Rev Gr Q/Q —
Earnings (next) 2026-08-03
Earnings (prior) 2026-05-04
ROA 12.14%
ROE 24.20%
ROIC —
Gross Margin 54.39%
Oper. Margin 38.13%
Profit Margin 35.51%
Shs Outstand 253.81M
Shs Float 253.01M
Insider Own 0.21%
Instit Own 97.37%
Short Float 1.86%
Short Ratio 3.69
Short Interest 4.17M
52W High 507.92
vs 52W High -11.74%
52W Low 362.50
vs 52W Low 23.67%
Beta 0.30
Impl. Vol. 0.00%
Rel Volume 1.06
Avg Volume 1.29M
Volume 1.37M
Target (mean) $549.50
Tgt Median $559.50
Tgt Low $330.00
Tgt High $641.00
# Analysts 28
Recom Buy
Prev Close $435.17
Price $448.29
Change 3.01%
About

Vertex Pharmaceuticals Incorporated operates as a biotechnology company in the United States, Europe, and internationally. The company offers transformative medicines for people with serious diseases with a focus on specialty markets, such as cystic fibrosis (CF), sickle cell disease (SCD), transfusion dependent beta thalassemia (TDT), and acute pain. It markets TRIKAFTA/KAFTRIO for people with CF with at least one F508del mutation for 2 years of age and older; ALYFTREK for the treatment for people with CF 6 years of age and older; SYMDEKO/SYMKEVI for treatment of patients with CF 6 years of age and older; ORKAMBI for CF patients 1 year or older; and KALYDECO for the treatment of patients with 1 month or older who have CF with ivacaftor. The company also develops CASGEVY for the treatment of SCD and TDT; JOURNAVX for the treatment of acute pain in adults; VX-522, a CFTR mRNA therapeutic designed to treat the underlying cause of CF, which is in Phase 1/2 clinical trial; inaxaplin for the treatment of APOL1-mediated kidney disease, which is in single Phase 2 trial; VX-264 for treating Type 1 Diabetes; VX-670 for the treatment of myotonic dystrophy type 1; and VX-407, a small molecule corrector for the treatment of autosomal dominant polycystic kidney disease. The company sells its products primarily to specialty pharmacy and distributors, wholesalers, retail pharmacies, hospitals, and clinics. Vertex Pharmaceuticals Incorporated was founded in 1989 and is headquartered in Boston, Massachusetts.

Valuation Models

Price estimates from analyst targets and simple models.

1. Analyst consensus
$549.50
Mean price target
2. Current target
$448.29
Latest analyst target
3. DCF / Fair value
$197.39
Simplified: (Free Cash Flow ÷ Shares) × 18 (P/FCF multiple). Not a …
Ratings
Current target
$448.29
Low
$330.00
High
$641.00
Mean
$549.50

Latest analyst rating changes

Date Action Analyst Rating Change Price Target
2026-05-06 main Barclays Overweight → Overweight $615
2026-05-05 main Canaccord Genuity Hold → Hold $436
2026-05-05 main Morgan Stanley Overweight → Overweight $616
2026-05-05 main Bernstein Outperform → Outperform $572
2026-05-05 main RBC Capital Outperform → Outperform $543
2026-04-30 main Canaccord Genuity Hold → Hold $437
2026-04-10 main Morgan Stanley Overweight → Overweight $612
2026-03-18 up Maxim Group Hold → Buy $575
2026-03-11 main Truist Securities Buy → Buy $525
2026-03-10 main Morgan Stanley Overweight → Overweight $596
2026-03-10 main B of A Securities Buy → Buy $598
2026-03-10 main Citigroup Buy → Buy $585
2026-03-10 main Oppenheimer Outperform → Outperform $600
2026-03-10 init Jefferies — → Buy $580
2026-03-10 main HC Wainwright & Co. Buy → Buy $641
2026-02-17 main Canaccord Genuity Hold → Hold $441
2026-02-17 main Barclays Overweight → Overweight $607
2026-02-17 main HC Wainwright& Co. Buy → Buy $591
2026-02-13 main Scotiabank Sector Perform → Sector Perform $558
2026-02-13 main RBC Capital Outperform → Outperform $541
News
RSS: Latest VRTX news
Insider Transactions
Filed Date Insider Relationship Transaction Shares Price Value SEC
2026-05-04 BHATIA SANGEETA N Director — 318 $423.73 $134,746
2026-05-01 MCKENZIE DIANA L Director — 943 $0.00 $0
2026-05-01 SCHNEIDER JENNIFER J Director — 472 $0.00 $0
2026-05-01 THORNBERRY NANCY A. Director — 472 $0.00 $0
2026-05-01 BHATIA SANGEETA N Director — 943 $0.00 $0
2026-05-01 GARBER ALAN M Director — 472 $0.00 $0
2026-05-01 LIU JOY Officer — 1,104 $425.02 $469,222
2026-04-01 LIU JOY Officer — 978 $449.17 $439,288
2026-03-27 BOZIC CARMEN Officer — 2,329 $450.95 $1,050,263
2026-03-13 BOZIC CARMEN Officer — 2,329 $481.79 $1,122,089
Financials
Statement View
Amounts in millions (2 decimals, no suffix) • EPS per share (2 decimals) • Trend = period evolution • YoY Growth = previous period %
Line Item Trend 2025-12-31 2024-12-31 2023-12-31 2022-12-31
Total Revenue
12,001.30
+8.90%
11,020.10
+11.66%
9,869.20
+10.51%
8,930.70
Operating Revenue
11,970.60
+8.63%
11,020.10
+11.66%
9,869.20
+10.51%
8,930.70
Cost Of Revenue
1,651.30
+7.89%
1,530.50
+21.26%
1,262.20
+16.84%
1,080.30
Reconciled Cost Of Revenue
1,651.30
+7.89%
1,530.50
+21.26%
1,262.20
+16.84%
1,080.30
Gross Profit
10,350.00
+9.07%
9,489.60
+10.25%
8,607.00
+9.64%
7,850.40
Operating Expense
5,795.60
-40.39%
9,723.00
+101.45%
4,826.60
+34.05%
3,600.50
Research And Development
4,042.50
-51.05%
8,258.70
+123.81%
3,690.00
+38.94%
2,655.80
Selling General And Administration
1,753.10
+19.72%
1,464.30
+28.83%
1,136.60
+20.31%
944.70
Total Expenses
7,446.90
-33.83%
11,253.50
+84.82%
6,088.80
+30.08%
4,680.80
Operating Income
4,554.40
+2051.33%
-233.40
-106.17%
3,780.40
-11.05%
4,249.90
Total Operating Income As Reported
4,173.30
+1891.88%
-232.90
-106.08%
3,832.00
-11.04%
4,307.40
EBITDA
4,866.30
+900.68%
486.30
-89.44%
4,605.20
+3.83%
4,435.50
Normalized EBITDA
5,247.40
+980.16%
485.80
-89.33%
4,553.60
+4.01%
4,378.00
Reconciled Depreciation
209.80
+1.25%
207.20
+14.29%
181.30
+22.25%
148.30
EBIT
4,656.50
+1568.40%
279.10
-93.69%
4,423.90
+3.19%
4,287.20
Total Unusual Items
-381.10
-76320.00%
0.50
-99.03%
51.60
-10.26%
57.50
Total Unusual Items Excluding Goodwill
-381.10
-76320.00%
0.50
-99.03%
51.60
-10.26%
57.50
Special Income Charges
-381.10
-76320.00%
0.50
-99.03%
51.60
-10.26%
57.50
Other Special Charges
—
4,628.40
+778.09%
527.10
+356.36%
115.50
Impairment Of Capital Assets
379.00
0.00
0.00
—
Restructuring And Mergern Acquisition
2.10
+520.00%
-0.50
+99.03%
-51.60
+10.26%
-57.50
Net Income
3,953.20
+838.09%
-535.60
-114.80%
3,619.60
+8.96%
3,322.00
Pretax Income
4,643.20
+1768.49%
248.50
-94.33%
4,379.80
+3.48%
4,232.40
Net Non Operating Interest Income Expense
477.60
-15.84%
567.50
-0.54%
570.60
+535.41%
89.80
Interest Expense Non Operating
13.30
-56.54%
30.60
-30.61%
44.10
-19.53%
54.80
Net Interest Income
477.60
-15.84%
567.50
-0.54%
570.60
+535.41%
89.80
Interest Expense
13.30
-56.54%
30.60
-30.61%
44.10
-19.53%
54.80
Interest Income Non Operating
490.90
-17.92%
598.10
-2.70%
614.70
+325.10%
144.60
Interest Income
490.90
-17.92%
598.10
-2.70%
614.70
+325.10%
144.60
Other Income Expense
-388.80
-354.21%
-85.60
-397.22%
28.80
+126.84%
-107.30
Other Non Operating Income Expenses
-7.70
+91.06%
-86.10
-277.63%
-22.80
+86.17%
-164.80
Tax Provision
690.00
-12.00%
784.10
+3.14%
760.20
-16.50%
910.40
Tax Rate For Calcs
0.00
-29.24%
0.00
+20.69%
0.00
-19.07%
0.00
Tax Effect Of Unusual Items
-56.63
-54036.32%
0.10
-98.83%
8.98
-27.37%
12.36
Net Income Including Noncontrolling Interests
3,953.20
+838.09%
-535.60
-114.80%
3,619.60
+8.96%
3,322.00
Net Income From Continuing Operation Net Minority Interest
3,953.20
+838.09%
-535.60
-114.80%
3,619.60
+8.96%
3,322.00
Net Income From Continuing And Discontinued Operation
3,953.20
+838.09%
-535.60
-114.80%
3,619.60
+8.96%
3,322.00
Net Income Continuous Operations
3,953.20
+838.09%
-535.60
-114.80%
3,619.60
+8.96%
3,322.00
Normalized Income
4,277.67
+898.08%
-536.00
-114.98%
3,576.98
+9.16%
3,276.86
Net Income Common Stockholders
3,953.20
+838.09%
-535.60
-114.80%
3,619.60
+8.96%
3,322.00
Diluted EPS
15.32
+836.54%
-2.08
-114.97%
13.89
+8.35%
12.82
Basic EPS
15.46
+843.27%
-2.08
-114.80%
14.05
+8.33%
12.97
Basic Average Shares
255.70
-0.85%
257.90
+0.08%
257.70
+0.62%
256.10
Diluted Average Shares
258.00
+0.04%
257.90
-1.00%
260.50
+0.54%
259.10
Diluted NI Availto Com Stockholders
3,953.20
+838.09%
-535.60
-114.80%
3,619.60
+8.96%
3,322.00
Line Item Trend 2023-12-31 2022-12-31
Total Assets
22,730.20
+25.23%
18,150.90
Current Assets
14,144.20
+6.87%
13,234.80
Cash Cash Equivalents And Short Term Investments
11,218.30
+4.08%
10,778.50
Cash And Cash Equivalents
10,369.10
-1.28%
10,504.00
Other Short Term Investments
849.20
+209.36%
274.50
Receivables
1,563.40
+8.40%
1,442.20
Accounts Receivable
1,563.40
+8.40%
1,442.20
Inventory
738.80
+60.40%
460.60
Raw Materials
78.70
+106.56%
38.10
Work In Process
525.10
+101.42%
260.70
Finished Goods
135.00
-16.56%
161.80
Prepaid Assets
537.60
+24.56%
431.60
Hedging Assets Current
1.80
-96.21%
47.50
Other Current Assets
84.30
+13.31%
74.40
Total Non Current Assets
8,586.00
+74.65%
4,916.10
Net PPE
1,452.90
-0.20%
1,455.80
Gross PPE
2,641.80
+6.39%
2,483.10
Accumulated Depreciation
-1,188.90
-15.73%
-1,027.30
Properties
0.00
0.00
Land And Improvements
33.10
+0.00%
33.10
Buildings And Improvements
928.60
+2.82%
903.10
Machinery Furniture Equipment
911.90
+15.64%
788.60
Other Properties
293.60
-15.49%
347.40
Leases
474.60
+15.50%
410.90
Goodwill And Other Intangible Assets
1,927.90
+13.97%
1,691.60
Goodwill
1,088.00
+0.00%
1,088.00
Other Intangible Assets
839.90
+39.15%
603.60
Investments And Advances
2,497.80
+2126.20%
112.20
Non Current Deferred Assets
1,812.10
+45.33%
1,246.90
Non Current Deferred Taxes Assets
1,812.10
+45.33%
1,246.90
Other Non Current Assets
895.30
+118.58%
409.60
Total Liabilities Net Minority Interest
5,149.80
+21.51%
4,238.20
Current Liabilities
3,547.40
+29.37%
2,742.10
Payables And Accrued Expenses
3,242.70
+33.41%
2,430.60
Payables
924.50
+43.96%
642.20
Accounts Payable
364.90
+20.07%
303.90
Other Payable
460.10
+114.00%
215.00
Current Accrued Expenses
2,318.20
+29.62%
1,788.40
Total Tax Payable
99.50
-19.30%
123.30
Current Debt And Capital Lease Obligation
83.70
-6.38%
89.40
Current Capital Lease Obligation
83.70
-6.38%
89.40
Current Deferred Liabilities
170.30
+6.70%
159.60
Current Deferred Revenue
170.30
+6.70%
159.60
Other Current Liabilities
50.70
-18.88%
62.50
Total Non Current Liabilities Net Minority Interest
1,602.40
+7.11%
1,496.10
Long Term Debt And Capital Lease Obligation
724.70
-10.56%
810.30
Long Term Capital Lease Obligation
724.70
-10.56%
810.30
Tradeand Other Payables Non Current
681.40
+50.49%
452.80
Other Non Current Liabilities
196.30
-15.75%
233.00
Stockholders Equity
17,580.40
+26.36%
13,912.70
Common Stock Equity
17,580.40
+26.36%
13,912.70
Capital Stock
2.60
+0.00%
2.60
Common Stock
2.60
+0.00%
2.60
Preferred Stock
0.00
0.00
Share Issued
257.70
+0.27%
257.01
Ordinary Shares Number
257.70
+0.27%
257.01
Treasury Shares Number
0.00
0.00
Additional Paid In Capital
7,449.70
+0.86%
7,386.50
Retained Earnings
10,142.40
+55.49%
6,522.80
Gains Losses Not Affecting Retained Earnings
-14.30
-1887.50%
0.80
Other Equity Adjustments
-14.30
-1887.50%
0.80
Total Equity Gross Minority Interest
17,580.40
+26.36%
13,912.70
Total Capitalization
17,580.40
+26.36%
13,912.70
Working Capital
10,596.80
+0.99%
10,492.70
Invested Capital
17,580.40
+26.36%
13,912.70
Total Debt
808.40
-10.15%
899.70
Capital Lease Obligations
808.40
-10.15%
899.70
Net Tangible Assets
15,652.50
+28.08%
12,221.10
Tangible Book Value
15,652.50
+28.08%
12,221.10
Available For Sale Securities
2,497.80
+2126.20%
112.20
Investmentin Financial Assets
2,497.80
+2126.20%
112.20
Line Item Trend 2025-12-31 2024-12-31 2023-12-31 2022-12-31
Operating Cash Flow
3,631.40
+837.19%
-492.60
-113.93%
3,537.30
-14.35%
4,129.90
Cash Flow From Continuing Operating Activities
3,631.40
+837.19%
-492.60
-113.93%
3,537.30
-14.35%
4,129.90
Net Income From Continuing Operations
3,953.20
+838.09%
-535.60
-114.80%
3,619.60
+8.96%
3,322.00
Depreciation Amortization Depletion
209.80
+1.25%
207.20
+14.29%
181.30
+22.25%
148.30
Depreciation
—
—
—
148.30
Depreciation And Amortization
209.80
+1.25%
207.20
+14.29%
181.30
+22.25%
148.30
Other Non Cash Items
113.40
+12500.00%
0.90
+102.11%
-42.60
+6.78%
-45.70
Stock Based Compensation
685.90
-1.80%
698.50
+20.18%
581.20
+18.30%
491.30
Asset Impairment Charge
379.00
0.00
0.00
—
Deferred Tax
-510.80
-46.44%
-348.80
+34.99%
-536.50
-94.45%
-275.90
Deferred Income Tax
-510.80
-46.44%
-348.80
+34.99%
-536.50
-94.45%
-275.90
Operating Gains Losses
—
57.70
+9516.67%
0.60
-99.60%
149.10
Gain Loss On Investment Securities
—
57.70
+9516.67%
0.60
-99.60%
149.10
Change In Working Capital
-1,199.10
-132.93%
-514.80
-93.75%
-265.70
-177.96%
340.80
Change In Receivables
-347.30
-249.75%
-99.30
-18.07%
-84.10
+76.55%
-358.60
Changes In Account Receivables
-347.30
-249.75%
-99.30
-18.07%
-84.10
+76.55%
-358.60
Change In Inventory
-524.20
-1.33%
-517.30
-60.20%
-322.90
-136.73%
-136.40
Change In Prepaid Assets
-396.00
-97.70%
-200.30
+63.29%
-545.70
-67.19%
-326.40
Change In Payables And Accrued Expense
-80.10
-130.53%
262.40
-45.12%
478.10
-27.92%
663.30
Change In Accrued Expense
-116.90
-154.91%
212.90
-50.42%
429.40
-20.85%
542.50
Change In Payable
36.80
-25.66%
49.50
+1.64%
48.70
-59.69%
120.80
Change In Account Payable
36.80
-25.66%
49.50
+1.64%
48.70
-59.69%
120.80
Change In Other Current Liabilities
148.50
+274.06%
39.70
-81.00%
208.90
-58.13%
498.90
Investing Cash Flow
-945.40
+74.92%
-3,770.00
-20.00%
-3,141.70
-878.42%
-321.10
Cash Flow From Continuing Investing Activities
-945.40
+74.92%
-3,770.00
-20.00%
-3,141.70
-878.42%
-321.10
Net PPE Purchase And Sale
-437.60
-46.99%
-297.70
-48.55%
-200.40
+2.10%
-204.70
Purchase Of PPE
-437.60
-46.99%
-297.70
-48.55%
-200.40
+2.10%
-204.70
Capital Expenditure
-437.60
+9.85%
-485.40
-87.85%
-258.40
-26.23%
-204.70
Net Investment Purchase And Sale
-483.10
+85.05%
-3,230.60
-13.26%
-2,852.30
-1354.86%
227.30
Purchase Of Investment
-6,396.50
+16.89%
-7,696.20
-103.25%
-3,786.50
-446.63%
-692.70
Sale Of Investment
5,913.40
+32.42%
4,465.60
+378.01%
934.20
+1.54%
920.00
Net Business Purchase And Sale
—
0.00
0.00
+100.00%
-295.90
Purchase Of Business
—
0.00
0.00
+100.00%
-295.90
Net Intangibles Purchase And Sale
0.00
+100.00%
-187.70
-223.62%
-58.00
0.00
Purchase Of Intangibles
0.00
+100.00%
-187.70
-223.62%
-58.00
0.00
Net Other Investing Changes
-24.70
+54.26%
-54.00
-74.19%
-31.00
+35.15%
-47.80
Financing Cash Flow
-2,261.30
-51.27%
-1,494.90
-165.90%
-562.20
-730.43%
-67.70
Cash Flow From Continuing Financing Activities
-2,261.30
-51.27%
-1,494.90
-165.90%
-562.20
-730.43%
-67.70
Net Issuance Payments Of Debt
-5.40
+83.93%
-33.60
+25.17%
-44.90
+47.49%
-85.50
Issuance Of Debt
—
—
1.80
0.00
Repayment Of Debt
-5.40
+83.93%
-33.60
+25.17%
-44.90
+47.49%
-85.50
Long Term Debt Issuance
—
—
1.80
0.00
Long Term Debt Payments
-5.40
+83.93%
-33.60
+25.17%
-44.90
+47.49%
-85.50
Net Long Term Debt Issuance
-5.40
+83.93%
-33.60
+25.17%
-44.90
+47.49%
-85.50
Net Common Stock Issuance
-2,387.30
-50.89%
-1,582.10
-142.02%
-653.70
-280.06%
-172.00
Common Stock Payments
-2,387.30
-50.89%
-1,582.10
-142.02%
-653.70
-280.06%
-172.00
Repurchase Of Capital Stock
-2,387.30
-50.89%
-1,582.10
-142.02%
-653.70
-280.06%
-172.00
Proceeds From Stock Option Exercised
127.70
+11.43%
114.60
-14.86%
134.60
-27.75%
186.30
Net Other Financing Charges
3.70
-40.32%
6.20
+244.44%
1.80
-48.57%
3.50
Changes In Cash
424.70
+107.38%
-5,757.50
-3355.88%
-166.60
-104.45%
3,741.10
Effect Of Exchange Rate Changes
90.90
+313.38%
-42.60
-258.36%
26.90
+192.12%
-29.20
Beginning Cash Position
4,572.20
-55.92%
10,372.30
-1.33%
10,512.00
+54.59%
6,800.10
End Cash Position
5,087.80
+11.28%
4,572.20
-55.92%
10,372.30
-1.33%
10,512.00
Free Cash Flow
3,193.80
+426.56%
-978.00
-129.83%
3,278.90
-16.47%
3,925.20
Interest Paid Supplemental Data
12.40
-59.34%
30.50
-29.23%
43.10
-17.59%
52.30
Income Tax Paid Supplemental Data
1,566.70
+44.78%
1,082.10
-35.49%
1,677.30
+58.56%
1,057.80
SEC Filings

Recent 10-K, 10-Q, 8-K, and Form 4 (insider) filings.

Trades
Date User Broker Pattern Type Position Size Entry Price Trade P&L Status
Posts
Published Title Author Category